

PUBLIKATIONSLISTE – ASSOC.-PROF. PD. DR. WOLFGANG WADSAK

Indices (Scopus 25/03/2019)

Peer-reviewed Originalarbeiten:	157
h-Index:	28
Total Cites:	2811

Erst-Autorschaften

- *) Wadsak W, Hrncek E, Irlweck K. Formation of americium(III) complexes with aqueous silicic acid. *Radiochimica Acta* 2000; **88**:61-64.
- *) Wadsak W and Mitterhauser M. Synthesis of [¹⁸F]FETO, a novel potential 11-β hydroxylase inhibitor. *Journal of Labelled Compounds and Radiopharmaceuticals* 2003; **46**:379-388.
- *) Wadsak W, Mitterhauser M, Mien LK, Tögel S, Keppler B, Dudczak R, Kletter K. Radiosynthesis of 3-(2'-[¹⁸F]Fluoro)-flumazenil ([¹⁸F]FFMZ). *Journal of Labelled Compounds and Radiopharmaceuticals* 2003; **46**:1229-1240.
- *) Wadsak W, Wirl-Sagadin B, Mitterhauser M, Mien LK, Ettlinger DE, Dudczak R, Kletter K. N.c.a. nucleophilic radiofluorination on substituted benzaldehydes for the preparation of [¹⁸F]fluorinated aromatic amino acids. *Applied Radiation and Isotopes* 2006; **64**:355-359.
- *) Wadsak W, Mitterhauser M, Rendl G, Schuetz M, Mien LK, Ettlinger DE, Dudczak R, Kletter K, Karanikas G. [¹⁸F]FETO for adrenocortical PET imaging: a pilot study in healthy volunteers. *European Journal of Nuclear Medicine and Molecular Imaging* 2006; **33**:669-672.
- *) Wadsak W, Mien LK, Ettlinger DE, Feitscher S, Lanzenberger R, Marton J, Dudczak R, Kletter K, Mitterhauser M. Preparation and Radiosynthesis of [¹⁸F]FE@CFN (2-[¹⁸F]fluoroethyl 4-[N-(1-oxopropyl)-N-phenylamino]-1-(2-phenylethyl)-4-piperidinecarboxylate), a Potential μ-Opioid Receptor Imaging Agent. *Radiochimica Acta* 2007; **95**:33-38.
- *) Wadsak W, Mien LK, Ettlinger DE, Lanzenberger R, Haeusler D, Dudczak R, Kletter K, Mitterhauser M. Simple and fully automated preparation of [carbonyl-¹¹C]WAY-100635. *Radiochimica Acta* 2007; **95**:417-422.
- *) Wadsak W, Mien LK, Ettlinger DE, Eidherr H, Haeusler D, Sindelar KM, Keppler BK, Dudczak R, Kletter K, Mitterhauser M. [¹⁸F]Fluoroethylations: Different strategies for the rapid translation of [¹¹C]methylated Radiotracers. *Nuclear Medicine and Biology* 2007; **34**:1019-1028.
- *) Wadsak W, Mien LK, Shanab K, Ettlinger DE, Haeusler D, Sindelar KM, Lanzenberger RR, Spreitzer H, Vierstein H, Keppler BK, Dudczak R, Kletter K, Mitterhauser M. Preparation and first evaluation of

[¹⁸F]FE@SUPPY: a new PET-Tracer for the Adenosine A₃ Receptor. *Nuclear Medicine and Biology* 2008; **35**:61-66.

- *) Wadsak W, Mien LK, Shanab K, Weber K, Schmidt B, Sindelar KM, Ettliger DE, Haeusler D, Spreitzer H, Keppler BK, Viernstein H, Dudczak R, Kletter K, Mitterhauser M. Radiosynthesis of the adenosine A₃ receptor ligand 5-(2-[¹⁸F]fluoroethyl) 2,4-diethyl-3-(ethylsulfanylcarbonyl)-6-phenylpyridine-5-carboxylate ([¹⁸F]FE@SUPPY). *Radiochimica Acta* 2008; **96**:119-124.
- *) Wadsak W and Mitterhauser M. Basics and principles of radiopharmaceuticals for PET/CT. *European Journal of Radiology* 2010; **73**:461-469.

Senior-Autorschaften

- *) Mitterhauser M and Wadsak W. [¹⁸F]FETO - a longer lived PET tracer for the measurement of 11-beta-hydroxylase activity. *Journal of Clinical Endocrinology and Metabolism* 2006; e-letter.
- *) Mitterhauser M and Wadsak W. Evaluation of novel tropane analogues. *Nuclear Medicine and Biology* 2007; **34**: 591-592.
- *) Haeusler D, Mien LK, Nics L, Ungersboeck J, Philippe C, Lanzenberger RR, Kletter K, Dudczak R, Mitterhauser M, Wadsak W. Simple and rapid preparation of [¹¹C]DASB with high quality and reliability for routine applications. *Applied Radiation and Isotopes* 2009; **67**:1654-1660.
- *) Haeusler D, Mitterhauser M, Mien LK, Shanab K, Lanzenberger RR, Schirmer E, Ungersboeck J, Nics L, Spreitzer H, Viernstein H, Dudczak R, Kletter K, Wadsak W. Radiosynthesis of a novel potential adenosine A₃ receptor ligand, 5-ethyl 2,4-diethyl-3-((2-[¹⁸F]fluoroethyl)sulfanylcarbonyl)-6-phenylpyridine-5-carboxylate ([¹⁸F]FE@SUPPY:2). *Radiochimica Acta* 2009; **97**:753-758.
- *) Mitterhauser M, Haeusler D, Mien LK, Ungersboeck J, Nics L, Lanzenberger R, Sindelar K, Viernstein H, Dudczak R, Kletter K, Spreitzer H, Wadsak W. Automatisierung und erste Evaluation von [¹⁸F]FE@SUPPY:2, ein alternatives PET-Tracer für den Adenosin A₃-Rezeptor: Ein Vergleich mit [¹⁸F]FE@SUPPY. *The Open Nuclear Medicine Journal* 2009; **1**:15-23.
- *) Ungersboeck J, Philippe C, Mien LK, Haeusler D, Shanab K, Lanzenberger R, Spreitzer H, Keppler BK, Dudczak R, Kletter K, Mitterhauser M, Wadsak W. Microchemische Präparation von [¹⁸F]FE@SUPPY und [¹⁸F]FE@SUPPY:2 – Vergleich mit konventionellen Radiosynthesen. *Nuclear Medicine and Biology* 2011; **38**:427-434.
- *) Philippe C, Haeusler D, Mitterhauser M, Ungersboeck J, Viernstein H, Dudczak R, Wadsak W. Optimierung der Radiosynthese des Alzheimer-Tracers 2-(4-N-[¹¹C]methylaminophenyl)-6-Hydroxybenzothiazol ([¹¹C]PIB). *Applied Radiation and Isotopes* 2011; **69**:1212-1217.
- *) Selivanova SV, Mu L, Ungersboeck J, Stellfeld T, Ametamey SM, Schibli R, Wadsak W. Single-step Radiofluorierung von Peptiden mit kontinuierlichem Fluss-Mikroreaktor. *Organic and Biomolecular Chemistry* 2012; **10**: 3871-3874.
- *) Ungersboeck J, Richter S, Collier TL, Mitterhauser M, Karanikas G, Lanzenberger R, Dudczak R, Wadsak W.

- Radiolabelling of [¹⁸F]altanserin – a microfluidic approach. *Nuclear Medicine and Biology* 2012; **39**:1087-1092.
- *) Philippe C, Schirmer E, Mitterhauser M, Shanab K, Spreitzer H, Viernstein H, Wadsak W. Radiosynthesis of [¹¹C]SNAP-7941 – the first PET-Tracer for the Melanin Concentrating Hormone Receptor 1 (MCHR1). *Applied Radiation and Isotopes* 2012; **70**:2287–2294.
 - *) Ungersboeck J, Philippe C, Haeusler D, Mitterhauser M, Lanzenberger R, Dudczak R, Wadsak W. Optimization of [¹¹C]DASB-synthesis: microfluidic and vessel-based methods. *Applied Radiation and Isotopes* 2012; **70**:2615–2620.
 - *) Philippe C, Ungersboeck J, Schirmer E, Zdravkovic M, Shanab K, Lanzenberger R, Spreitzer H, Viernstein H, Mitterhauser M, Wadsak W. [¹⁸F]FE@SNAP - a new PET tracer for the Melanin Concentrating Hormone Receptor 1 (MCHR1): microfluidic and vessel-based approaches. *Bioorganic and Medicinal Chemistry* 2012; **20**:5936-5940.
 - *) Mark C, Bornatowicz B, Nics L, Haeusler D, Hendl M, Berger M, Lanzenberger R, Karanikas G, Spreitzer H,, Mitterhauser M, Wadsak W. Development and evaluation of a novel PET tracer for the norepinephrine transporter: [¹¹C]Me@APPI. *Nuclear Medicine and Biology* 2013; **40**:295-303.
 - *) Rami-Mark C, Ungersboeck J, Haeusler D, Nics L, Philippe C, Mitterhauser M, Willeit M, Lanzenberger R, Karanikas G, Wadsak W. Reliable set-up for in-loop ¹¹C-carboxylations using Grignard reactions for the preparation of [carbonyl-¹¹C]WAY-100635 and [¹¹C]-(+)-PHNO. *Applied Radiation and Isotopes* 2013; **82**:75-80.
 - *) Rami-Mark C, Zhang MR, Mitterhauser M, Lanzenberger R, Hacker M, Wadsak W. [¹⁸F]FMeNER-D2: Reliable fully-automated synthesis for clinical visualization of the norepinephrine transporter. *Nuclear Medicine and Biology* 2013;**40**:1049-1054.
 - *) Rami-Mark C, Bornatowicz B, Fink C, Otter P, Ungersboeck J, Vranka C, Haeusler D, Nics L, Spreitzer H, Hacker M, Mitterhauser M, Wadsak W. Synthesis, radiosynthesis and first in-vitro evaluation of novel PET-tracers for the dopamine transporter: [¹¹C]IPCIT and [¹⁸F]FE@IPCIT. *Bioorganic and Medicinal Chemistry* 2013; **21**:7562-7569.
 - *) Mitterhauser M and Wadsak W. Imaging Biomarkers or Biomarker Imaging? *Pharmaceuticals* 2014;**7**:765-778.
 - *) Philippe C, Zeilinger M, Mitterhauser M, Dumanic M, Lanzenberger R, Hacker M, Wadsak W. Parameter evaluation and fully-automated radiosynthesis of [¹¹C]harmine for imaging of MAO-A for clinical trials. *Applied Radiation and Isotopes* 2015; **97**:182–187.
 - *) Rami-Mark C, Berroterán-Infante N., Philippe C, Foltin S, Vranka C, Hoepfing A, Lanzenberger R, Hacker M, Mitterhauser M*, Wadsak W*. Radiosynthesis and first preclinical evaluation of the novel norepinephrine transporter PET-Ligand [¹¹C]Me@HAPTHI. *European Journal of Nuclear Medicine and Molecular Imaging Research* 2015;**5**(1):113.

- *) Rami-Mark C, Eberher N, Berroterán-Infante N, Vanicek T, Nics L, Lanzenberger R, Hacker M, Wadsak W*, Mitterhauser M*. [¹⁸F]FMeNER-D2: A systematic in vitro analysis of radio-metabolism. *Nuclear Medicine and Biology* 2016;**43**:490-495.
- *) Nics L, Steiner B, Klebermass EM, Philippe C, Mitterhauser M, Hacker M, Wadsak W. Speed matters to raise molar radioactivity: Fast HPLC shortens the quality control of C-11 PET-tracers. *Nuclear Medicine and Biology* 2018;**57**:28-33.
- *) Berroterán-Infante N, Balber T, Fuerlinger P, Bergmann M, Lanzenberger R, Hacker M, Mitterhauser M, Wadsak W. [¹⁸F]FEPPA: Improved Automated Radiosynthesis, Binding Affinity Profile and Preliminary in Vitro Evaluation in Colorectal Cancer. *ACS Medicinal Chemistry Letters* 2018; **9**:177-181.
- *) Pfaff S, Philippe C, Pichler V, Hacker M, Mitterhauser M, Wadsak W. Microfluidic ⁶⁸Ga-labeling: A proof of principle study. *Dalton Transactions* 2018;**47**:5997-6004.
- *) Philippe C, Mairinger S, Pichler V, Stanek J, Nics L, Mitterhauser M, Hacker M, Wanek T, Langer O, Wadsak W. Comparison of fully-automated radiosyntheses of [¹¹C]erlotinib for preclinical and clinical use starting from in target produced [¹¹C]CO₂ or [¹¹C]CH₄. *EJNMMI Radiopharm Chem.* 2018;**3**(1):8.
- *) Pichler V, Berroteran-Infante N, Philippe C, Vraka C, Klebermass EM, Balber T, Pfaff S, Nics L, Mitterhauser M, Wadsak W. An overview on PET radiochemistry: part 1 - covalent labels - ¹⁸F, ¹¹C, and ¹³N. *The Journal of Nuclear Medicine* 2018;**59**:1350-1354.
- *) Pichler V, Zenz T, Philippe C, Vraka V, Berroterán-Infante N, Pfaff S, Nics L, Ozenil M, Langer O, Willeit M, Traub-Weidinger T, Lanzenberger R, Mitterhauser M, Hacker M, Wadsak W. Molar activity - the bugaboo in ¹¹C-radiochemistry: an explorative study using the gas phase method. *Nuclear Medicine and Biology* 2018;**67**:21-26.
- *) Pfaff S, Nehring T, Pichler V, Cardinale J, Mitterhauser M, Hacker M, Wadsak W. Development and evaluation of a rapid analysis for HEPES determination in ⁶⁸Ga-radiotracers. *EJNMMI Research.* 2018;**8**:95.
- *) Pichler V, Vraka V, Berroterán-Infante N, Krcal A, Eidherr H, Traub-Weidinger T, Hacker M, Mitterhauser M, Wadsak W. L-[S-methyl-¹¹C]methionine - an example of radiosynthetic optimization. *Applied Radiation and Isotopes* 2018;**141**:107-111.
- *) Kalina T, Berroterán-Infante N, Schmitl S, Vraka C, Hacker M, Mitterhauser M, Pallitsch K*, Wadsak W*. Synthesis and in vitro evaluation of new translocator protein ligands designed for positron emission tomography. *Future Med Chem.* 2019 Mar 19. doi: 10.4155/fmc-2018-0444. [Epub ahead of print]
- *) Vraka C, Pichler V, Berroterán-Infante N, Wollenweber T, Pillinger A, Hohensinner M, Fetty L, Beitzke D, Li X, Philippe C, Pallitsch K, Mitterhauser M, Hacker M, Wadsak W. Optimization of the automated synthesis of [¹¹C]mHED – administered and apparent molar activities. *Pharmaceuticals (Basel)* 2019;**12**(1).

Co-Autorschaften

- *) Langer O, Mitterhauser M, Brunner M, Zeitlinger M, Wadsak W, Mayer BX, Kletter K, Müller M. Synthesis of fluorine-¹⁸-labeled Ciprofloxacin for Pet studies in humans. *Nuclear Medicine and Biology* 2003; **30**:285-291.

- *) Langer O, Mitterhauser M, Wadsak W, Brunner M, Müller U, Kletter K, Müller M. A general method for the fluorine-18 labelling of fluoroquinolone antibiotics. *Journal of Labelled Compounds and Radiopharmaceuticals* 2003; **46**: 715-727.
- *) Becherer A, Karanikas G, Szabó M, Georg G, Asenbaum S, Marosi C, Henk C, Wunderbaldinger P, Czech T, Wadsak W, Kletter K. Brain tumour imaging with PET: a comparison between [¹⁸F]fluorodopa and [¹¹C]methionine. *European Journal of Nuclear Medicine and Molecular Imaging* 2003; **30**: 1561-1566.
- *) Mitterhauser M, Wadsak W, Langer O, Schmaljohann J, Zetting G, Dudczak R, Viernstein H, Kletter K. Comparison of three different purification methods for the routine preparation of [¹¹C] Metomidate. *Applied Radiation and Isotopes* 2003; **59**: 125-128.
- *) Mitterhauser M, Wadsak W, Wabnegger L, Sieghart W, Viernstein H, Kletter K, Dudczak R. In vivo and in vitro evaluation of [¹⁸F]FETO on the adrenocortical and GABAergic System in rats. *European Journal of Nuclear Medicine and Molecular Imaging* 2003; **30**:1398-1401.
- *) Mitterhauser M, Wadsak W, Mien LK, Eidherr H, Roka S, Zetting G, Angelberger P, Viernstein H, Kletter K, Dudczak R. The labelling of Nanocoll® with [¹¹¹In] for dual-isotope scanning. *Applied Radiation and Isotopes* 2003; **59**: 337-342.
- *) Mitterhauser M, Wadsak W, Eidherr H, Krcal A, Kletter K, Dudczak R, Viernstein H, Pirich C. Labelling of EDTMP (Multibone) with [¹¹¹In], [^{99m}Tc] and [¹⁸⁸Re] using different carriers for “cross complexation”. *Applied Radiation and Isotopes* 2004; **60**: 653-658.
- *) Mitterhauser M, Wadsak W, Wabnegger L, Mien LK, Tögel S, Langer O, Sieghart W, Viernstein H, Kletter K, Dudczak R. In vivo and in vitro evaluation of [¹⁸F]fluoroflumazenil ([¹⁸F]FFMZ) on rats. *Nuclear Medicine and Biology* 2004; **31**: 291-295.
- *) Föger B, Mitterhauser M, Wadsak W, Ofluoglu S, Traub T, Karanikas G, Dudczak R, Pirich C. Bone lesion detection with carrier added Tc-99m EDTMP in comparison to Tc-99m DPD. *Nuclear Medicine Communications* 2004; **25**: 361-365.
- *) Mitterhauser M, Tögel S, Wadsak W, Mien LK, Eidherr H, Wiesner K, Viernstein H, Kletter K, Dudczak R. Binding studies of [¹⁸F]-fluoride and Polyphosphonates radiolabelled with [¹¹¹In], [^{99m}Tc], [¹⁵³Sm] and [¹⁸⁸Re] on bone compartments: A new model for the pre vivo-evaluation of bone seekers? *Bone* 2004; **34**: 835-844.
- *) Mitterhauser M, Wadsak W, Krcal A, Schmaljohann J, Bartosch E, Eidherr H, Viernstein H, Kletter K. New aspects on the preparation of [¹¹C]Acetate – a simple and fast approach via distillation. *Applied Radiation and Isotopes* 2004, **61**: 1147-1150.
- *) Zetting G, Mitterhauser M, Wadsak W, Becherer A, Pirich C, Vierhapper H, Niederle B, Dudczak R, Kletter K. Positron emission tomography imaging of adrenal masses: F-18 Fluorodesoxyglucose and the 11-beta hydroxylase-tracer C-11-metomidate. *European Journal of Nuclear Medicine and Molecular Imaging* 2004; **31**: 1224-1230.
- *) Brunner M, Langer O, Dobrozemsky G, Müller U, Zeitlinger M, Mitterhauser M, Wadsak W, Dudczak R, Kletter K, Müller M. [¹⁸F]Ciprofloxacin, a new positron emission tomography tracer for noninvasive assessment of

the tissue distribution and pharmacokinetics of Ciprofloxacin in humans. *Antimicrobial Agents and Chemotherapy* 2004;**48**: 3850-3857.

- * Mitterhauser M, Wadsak W, Mien LK, Hoepfing A, Viernstein H, Dudczak R, Kletter K. Synthesis and Biodistribution of [¹⁸F]FE@CIT, a new potential tracer for the Dopamine Transporter. *Synapse* 2005, **55**: 73-79.
- * Langer O, Brunner M, Zeitlinger M, Ziegler S, Müller U, Dobrozemsky G, Lackner E, Joukhader C, Mitterhauser M, Wadsak W, Minar E, Dudczak R, Kletter K, Müller M. In vitro and in vivo evaluation of [¹⁸F]ciprofloxacin for the imaging of bacterial infections with PET. *European Journal of Nuclear Medicine and Molecular Imaging* 2005; **32**: 143-150.
- * Mitterhauser M, Wadsak W, Krcal A, Schmaljohann J, Eidherr H, Viernstein H, Kletter K. New aspects on the preparation of [¹¹C]Methionine – a simple and fast online approach without preparative HPLC. *Applied Radiation and Isotopes* 2005; **62**: 441-445.
- * Brunner M, Langer O, Sunder-Plassmann R, Dobrozemsky G, Müller U, Wadsak W, Krcal A, Karch R, Mannhalter C, Dudczak R, Kletter K, Steiner I, Baumgartner C, Müller M. Influence of functional haplotypes in the drug transporter gene ABCB1 on CNS drug distribution in humans. *Clinical Pharmacology and Therapeutics* 2005; **78**: 182-190.
- * Mitterhauser M, Toegel S, Wadsak W, Mien KL, Eidherr H, Kletter K, Viernstein H, Kluger R, Engel A, Dudczak R. Binding studies of [¹⁸F]-fluoride and polyphosphonates radiolabelled with [^{99m}Tc], [¹¹¹In], [¹⁵³Sm] and [¹⁸⁸Re] on bone compartments: Verification of the pre vivo model? *Bone* 2005; **37**: 404-412.
- * Khorsand A, Graf S, Eidherr H, Wadsak W, Kletter K, Sochor H, Schuster E, Porenta G. Gated cardiac ¹³NH₃ PET for assessment of left ventricular volumes, mass, and ejection fraction: Comparison with electrocardiography-gated ¹⁸F-FDG PET. *The Journal of Nuclear Medicine* 2005; **46**: 2009-2013.
- * Toegel S, Hoffmann O, Wadsak W, Ettliger DE, MienLK, Wiesner K, Nguemo J, Viernstein H, Kletter K, Dudczak R, Mitterhauser M. Uptake of bone seekers is solely associated with mineralisation! A study with [^{99m}Tc]-MDP, [¹⁵³Sm]-EDTMP and [¹⁸F]-fluoride on osteoblasts. *European Journal of Nuclear Medicine and Molecular Imaging* 2006; **33**: 491-494.
- * Ettliger DE, Wadsak W, MienLK, Machek M, Wabnegger L, Rendl G, Karanikas G, Viernstein H, Kletter K, Dudczak R, Mitterhauser M. [¹⁸F]FETO: metabolic considerations. *European Journal of Nuclear Medicine and Molecular Imaging* 2006; **33**: 928-931.
- * Ettliger DE, Mitterhauser M, Wadsak W, Ostermann E, Farkouh A, Schueller J, Czejka M. In vivo disposition of Irinotecan (CPT-11) and its metabolites in combination with the monoclonal antibody Cetuximab. *Anticancer Research* 2006; **26**: 1337-1342.
- * Mitterhauser M, Dobrozemsky G, Zettinig G, Wadsak W, Vierhapper H, Dudczak R, Kletter K. Imaging of adrenocortical metastases with [¹¹C]metomidate. *European Journal of Nuclear Medicine and Molecular Imaging* 2006; **33**: 974.

- *) Toegel S, Mien LK, Wadsak W, Eidherr H, Viernstein H, Kluger R, Ettlenger D, Kletter K, Dudczak R, Mitterhauser M. In vitro evaluation of no carrier added, carrier added and cross-complexed [⁹⁰Y]-EDTMP provides evidence for a novel “foreign carrier theory”. *Nuclear Medicine and Biology* 2006; **33**: 95-99.
- *) Lanzenberger RR, Mitterhauser M, Spindelegger C, Wadsak W, Klein N, Mien LK, Holik A, Attarbaschi T, Mossaheb N, Sacher J, Geiss-Granadia T, Kletter K, Kasper S, Tauscher J. Reduced serotonin-1A receptor binding in social anxiety disorder. *Biological Psychiatry* 2007; **61**: 1081-1089.
- *) Mitterhauser M, Toegel S, Wadsak W, Lanzenberger R, Mien LK, Kuntner C, Wanek T, Eidherr H, Ettlenger DE, Viernstein H, Kluger R, Dudczak R, Kletter K. Pre-, Ex- and In-vivo Evaluation of [⁶⁸Ga]-EDTMP. *Nuclear Medicine and Biology* 2007; **34**: 391-397.
- *) Fischer MB, Ruger B, Vaculik C, Becherer A, Wadsak W, Yanagida G, Losert UM, Chen J, Carroll MC, Eibl MM. The presence of MOMA-2(+) macrophages in the outer B cell zone and protection of the splenic micro-architecture from LPS-induced destruction depend on secreted IgM. *European Journal of Immunology* 2007; **37**: 2825-2833.
- *) Toegel S, Wadsak W, Mien LK, Viernstein H, Kluger R, Eidherr H, Haeusler D, Kletter K, Dudczak R, Mitterhauser M. Preparation and pre-vivo evaluation of no-carrier-added, carrier-added and cross-complexed [⁶⁸Ga]-EDTMP formulations. *European Journal of Pharmaceutics and Biopharmaceutics*; 2008; **68**: 406-412.
- *) Shanab K, Wadsak W, Mien LK, Mitterhauser M, Holzer W, Polster V, Spreitzer H. Synthesis of in vivo metabolites of the new Adenosine A3 receptor PET-radiotracer [18F]FE@SUPPY. *Heterocycles* 2008; **75**: 339-356.
- *) Ettlenger DE, Haeusler D, Wadsak W, Girschele F, Sindelar KM, Mien LK, Ungersboeck J, Viernstein H, Kletter K, Dudczak R, Mitterhauser M. Metabolism and Autoradiographic Evaluation of [18F]FE@CIT: A comparison with [123I]β-CIT and [123I]FP-CIT. *Nuclear Medicine and Biology* 2008; **35**: 475-479.
- *) Gerstl F, Windischberger C, Mitterhauser M, Wadsak W, Holik A, Kletter K, Moser E, Kasper S, Lanzenberger R. Multimodal imaging of human early visual cortex by combining functional and molecular measurements with fMRI and PET. *NeuroImage* 2008; **41**:204-211.
- *) BankstahlJP, Kuntner C, Abraham A, Karch R, Stanek J, Wanek T, Zsebedics M, Wadsak W, Kletter K, Kvaternik H, Müller M, Löscher W, Langer O. Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-¹¹C-verapamil and PET. *Journal of Nuclear Medicine* 2008; **49**: 1328-1335.
- *) Stein P, Savli M, Wadsak W, Mitterhauser M, Fink M, Spindelegger C, Mien LK, Moser U, Dudczak R, Kletter K, Kasper S, Lanzenberger R. The serotonin-1A receptor distribution in healthy men and women measured by PET and [carbonyl-¹¹C]WAY-100635. *European Journal of Nuclear Medicine and Molecular Imaging* 2008; **35**:2159–2168.
- *) Spindelegger C, Lanzenberger R, Wadsak W, Mien LK, Stein P, Mitterhauser M, Moser U, Holik A, Kletter K, Kasper S. Influence of escitalopram treatment on 5-HT1A receptor binding in limbic regions in patients with anxiety disorders. *Molecular Psychiatry* 2009; **14**: 1040-50.

- *) Witte V, Flöel A, Stein P, Savli M, Mien LK, Wadsak W, Spindelegger C, Moser U, Fink M, Hahn A, Mitterhauser M, Kletter K, Kasper S, Lanzenberger R. Aggression is related to frontal serotonin-1A receptor distribution as revealed by PET in healthy subjects. *Human Brain Mapping* 2009; **30**:2558-2570.
- *) Fink M, Wadsak W, Savli M, Stein P, Moser U, Hahn A, Mien LK, Kletter K, Mitterhauser M, Kasper S, Lanzenberger R. Lateralization of serotonin-1A receptor distribution in language areas associated with sex. *NeuroImage* 2009; **45**(2):598-605.
- *) Philippe C, Mien LK, Salar-Behzadi S, Knaeusl B, Wadsak W, Dudczak R, Kletter K, Viernstein H, Mitterhauser M. "Label and go"- a fast and easy radiolabelling method for pellets. *Applied Radiation and Isotopes* 2010; **68**:399-403.
- *) Haeusler D, Nics L, Mien LK, Ungersboeck J, Lanzenberger RR, Shanab K, Sindelar KM, Viernstein H, Wagner KH, Dudczak R, Kletter K, Wadsak W, Mitterhauser M. [¹⁸F]FE@SUPPY and [¹⁸F]FE@SUPPY:2 - Metabolic considerations. *Nuclear Medicine and Biology* 2010; **37**:421-426.
- *) Moser U, Wadsak W, Spindelegger C, Mitterhauser M, Mien LK, Bieglmayer C, Kletter K, Kasper S, Lanzenberger R. Hypothalamic serotonin-1A receptor binding measured by PET predicts the plasma level of dehydroepiandrosterone sulfate in healthy women. *Neuroscience Letters* 2010; **476**:161-165.
- *) Lanzenberger R, Wadsak W, Spindelegger C, Mitterhauser M, Akimova E, Mien LK, Fink M, Moser U, Savli M, Kranz C, Hahn A, Kletter K, Kasper S. Cortisol plasma levels in social anxiety disorder patients correlate with serotonin-1A receptor binding in limbic brain regions. *International Journal of Neuropsychopharmacology* 2010; **13**:1129-1143.
- *) Assem-Hilger E, Lanzenberger R, Savli M, Wadsak W, Mitterhauser M, Mien LK, Stoegmann E, Baumgartner C, Kletter K, Asenbaum S. Central 5-HT_{1A} receptor binding in Temporal Lobe Epilepsy: a [¹¹C]WAY-100635 PET study. *Epilepsy and Behaviour* 2010; **19**:467-473.
- *) Hahn A, Lanzenberger R, Wadsak W, Spindelegger C, Moser U, Mien LK, Mitterhauser M, Kasper S. Escitalopram enhances the association of serotonin-1A autoreceptors to heteroreceptors in anxiety disorders. *Journal of Neuroscience* 2010; **30**:14482-14489.
- *) Nics L, Haeusler D, Wadsak W, Wagner KH, Dudczak R, Kletter K, Mitterhauser M. The stability of methyl-, ethyl-, and fluoroethyl-esters against Carboxylesterases in-vitro: there is no difference. *Nuclear Medicine and Biology* 2011; **38**:13-17.
- *) Lanzenberger R, Mitterhauser M, Kranz GS, Spindelegger C, Wadsak W, Stein P, Moser U, Kletter K, Kasper S. Progesterone level predicts serotonin-1A receptor binding in the male human brain. *Neuroendocrinology* 2011; **94**: 84-88.
- *) Spindelegger C, Stein P, Wadsak W, Fink M, Mitterhauser M, Moser U, Savli M, Mien LK, Akimova E, Hahn A, Willeit M, Kletter K, Kasper S, Lanzenberger R. Light-dependent alteration of serotonin-1A receptor binding in cortical and subcortical limbic regions in the human brain. *World J Biol Psychiatry* 2012; **13**:413-22.
- *) Bauer M, Zeitlinger M, Karch R, Matzneller P, Stanek J, Jäger W, Böhmendorfer M, Wadsak W, Mitterhauser M, Bankstahl JP, Löscher W, Koepp M, Kuntner C, Müller M, Langer O. Pgp-Mediated Interaction Between (R)-

[11C]Verapamil and Tariquidar at the Human Blood-Brain Barrier: A Comparison With Rat Data. *Clinical Pharmacology and Therapeutics* 2012; **91**:227-33.

- *) Hahn A, Wadsak W, Windischberger C, Baldinger P, Höflich A, Losak J, Nics L, Philippe C, Kranz G, Kraus C, Mitterhauser M, Karanikas G, Kasper S, Lanzenberger R. Differential modulation of the default mode network via serotonin-1A receptors. *Proceedings of the National Academy of Sciences of the USA* 2012; **109**:2619-24.
- *) Baldinger P, Hahn A, Friedl M, Kranz GS, Ungersboeck J, Hoeflich A, Mitterhauser M, Rujescu D, Wadsak W, Lanzenberger R, Kasper S. Influence of the HTR1A polymorphism rs878567 on the serotonin 1a binding potential in vivo. [Einfluss des HTR1A-polymorphismus rs878567 auf das serotonin-1A- bindungspotenzial in vivo.] *Journal für Neurologie, Neurochirurgie und Psychiatrie* 2012;**13**:36-38.
- *) Hahn A, Nics L, Baldinger P, Ungersboeck J, Schuetz M, Frey R, Birkfellner W, Mitterhauser M, Wadsak W, , Karanikas G, Kasper S, Lanzenberger R. Combining image-derived and venous input functions enables quantification of serotonin-1A receptors with [*carbonyl*-¹¹C]WAY-100635 independent of arterial sampling. *Neuroimage* 2012; **62**:199–206.
- *) Lanzenberger R, Baldinger P, Hahn A, Ungersboeck J, Mitterhauser M, Winkler D, Micskei Z, Stein P, Karanikas G, Wadsak W, Kasper S, Frey R. Global decrease of serotonin-1A receptor binding after electroconvulsive therapy in major depression measured by PET. *Molecular Psychiatry* 2013; **18**:93-100.
- *) Lanzenberger R, Baldinger P, Hahn A, Ungersboeck J, Mitterhauser M, Winkler D, Micskei Z. Stein P, Karanikas G, Wadsak W, Kasper S, Frey R. Impact of electroconvulsive therapy on 5-HT1A receptor binding in major depression. *Molecular Psychiatry* 2013; **18**:1.
- *) Savli M, Bauer A, Mitterhauser M, Ding YS, Hahn A, Kroll T, Neumeister A, Haeusler D, Ungersboeck J, Henry S, Isfahani SA, Rattay F, Wadsak W, Kasper S, Lanzenberger R. Normative database of the serotonergic system in healthy subjects using multi-tracer PET. *Neuroimage* 2012; **63**:447-459.
- *) Lanzenberger R, Kranz GS, Haeusler D, Akimova E, Savli M, Hahn A, Wadsak W, Spindelegger C, Philippe C, Fink M, Mitterhauser M, Kasper S. Prediction of SSRI treatment response in major depression based on serotonin transporter interplay between median raphe nucleus and projection areas. *Neuroimage* 2012; **63**:874-881.
- *) Kraus C, Hahn A, Savli M, Kranz GS, Baldinger P, Höflich A, Spindelegger C, Ungersboeck J, Haeusler D, Mitterhauser M, Windischberger C, Wadsak W, Kasper S, Lanzenberger R. Serotonin-1A receptor binding is positively associated gray matter volume – A multimodal neuroimaging study combining PET and structural MRI. *Neuroimage* 2012; **63**:1091-1098.
- *) Nics L, Hahn A, Zeilinger M, Vraka C, Ungersboeck J, Haeusler D, Hartmann S, Wagner KH, Dudczak R, Lanzenberger R, Wadsak W, Mitterhauser M. Quantification of the serotonin-1A receptor radioligand [*carbonyl*-¹¹C]WAY-100635 and its radio-metabolites in human plasma: An improved HPLC-assay allowing two parallel patients. *Applied Radiation and Isotopes* 2012; **70**:2730-2736.
- *) Hahn A, Nics L, Baldinger P, Wadsak W, Savli M, Kraus C, Birkfellner W, Ungersboeck J, Haeusler D, Mitterhauser M, Karanikas G, Kasper S, Frey R, Lanzenberger R. Application of image-derived and venous

input functions in major depression using [*carbonyl*-¹¹C]WAY-100635. *Nuclear Medicine and Biology* 2013; **40**:371-377.

- *) Mayerhoefer ME, Ba-Ssalamah A, Weber M, Mitterhauser M, Eidherr H, Wadsak W, Trattnig S, Herneth A, Karanikas G. Gadoxetate-enhanced versus Diffusion-weighted MRI for Fused 68Ga-DOTANOC PET/MRI in Patients with Neuroendocrine Tumors of the Upper Abdomen. *European Radiology* 2013; **23**:1978-85.
- *) Bauer M, Karch R, Zeitlinger M, Stanek J, Philippe C, Wadsak W, Mitterhauser M, Jäger W, Haslachner H, Müller M, Langer O. Interaction of ¹¹C-tarividar and ¹¹C-elacridar with P-glycoprotein and breast cancer resistance protein at the human blood-brain barrier. *Journal of Nuclear Medicine* 2013; **54**:1181-1187.
- *) Philippe C, Nics L, Zeilinger M, Kuntner C, Wanek T, Mairinger S, Shanab K, Spreitzer H, Viernstein H, Wadsak W, Mitterhauser M. Preclinical in vitro & in vivo evaluation of [¹¹C]SNAP-7941 - the first PET tracer for the melanin concentrating hormone receptor 1. *Nuclear Medicine and Biology* 2013; **40**:919-925.
- *) Toth DF, Raderer M, Wadsak W, Karanikas G. Beta-2 Microglobulin as a Diagnostic Parameter in Non-Hodgkin Lymphoma: A Comparative Study with FDG-PET. *Anticancer Research* 2013; **33**:3341-3345.
- *) Philippe C, Nics L, Zeilinger M, Schirmer E, Spreitzer H, Karanikas G, Lanzenberger R, Viernstein H, Wadsak W, Mitterhauser M. Preparation and first preclinical evaluation of [¹⁸F]FE@SNAP: a new PET tracer for the melanin concentrating hormone receptor 1 (MCHR1). *Scientia Pharmaceutica* 2013; **81**:625-639.
- *) Schirmer E, Shanab K, Datterl B, Neudorfer C, Mitterhauser M, Wadsak W, Philippe C, Spreitzer H. Syntheses of precursors and reference compounds of the MCHR1 PET tracers [¹¹C]SNAP-7941 and [¹⁸F]FE@SNAP. *Molecules* 2013; **18**:12119-12143.
- *) Kranz GS, Hahn A, Baldinger P, Häusler D, Philippe C, Kaufmann U, Wadsak W, Savli M, Höflich A, Kraus C, Vanicek T, Mitterhauser M, Kasper S, Lanzenberger R. Cerebral serotonin transporter asymmetry in males and male-to-female transsexuals: a PET study with [¹¹C]DASB. *Brain Structure and Function* 2014; **219**:171-183.
- *) Baldinger P, Hahn A, Mitterhauser M, Kranz G, Friedl M, Wadsak W, Kraus C, Ungersböck J, Hartmann A, Giegling I, Rujescu D, Kasper S, Lanzenberger R. Impact of COMT genotype on serotonin-1A receptor binding investigated with PET. *Brain Structure and Function* 2014; **219**:2017-2028.
- *) Baldinger P, Kranz GS, Häusler D, Savli M, Spies M, Philippe C, Hahn A, Höflich A, Wadsak W, Mitterhauser M, Lanzenberger R, Kasper S. Regional differences in SERT occupancy after acute and prolonged SSRI intake investigated by brain PET. *NeuroImage* 2014; **88**:252-262.
- *) Hahn A, Häusler D, Kraus C, Höflich A, Kranz GS, Baldinger P, Savli M, Mitterhauser M, Wadsak W, Karanikas G, Kasper S, Lanzenberger R. Attenuated serotonin transporter association between midbrain dorsal raphe and ventral striatum in major depression. *Human Brain Mapping* 2014; **35**:3857-3866.
- *) Shanab K, Neudorfer C, Holzer W, Mitterhauser M, Wadsak W, Spreitzer H. A one-step microwave assisted synthetic method for an O/S-chemoselective route to derivatives of the first adenosine A3 PET radiotracer. *Molecules* 2014; **19**:4076-4082.

- *) Philippe C*, Haeusler D*, Fuchshuber F, Spreitzer H, Viernstein H, Hacker M, Wadsak W, Mitterhauser M. Comparative in-vitro autoradiographic investigation of the melanin concentrating hormone receptor 1 in the central nervous system. *European Journal of Pharmacology* 2014; **735C**:177-183.
- *) Stein P, Baldinger P, Kaufmann U, Rami-Mark C, Hahn A, Höflich A, Kranz GS, Savli M, Wadsak W, Mitterhauser M, Winkler D, Kasper S, Lanzenberger R. Relation of progesterone and DHEAS serum levels to 5-HT1A receptor binding potential in pre- and postmenopausal women. *Psychoneuroendocrinology* 2014; **46**:52-63.
- *) Kranz GS, Rami-Mark C, Kaufmann U, Baldinger P, Hahn A, Höflich A, Savli M, Stein P, Wadsak W, Mitterhauser M, Winkler D, Lanzenberger R, Kasper S. Effects of hormone replacement therapy on cerebral serotonin-1A receptor binding in postmenopausal women examined with [*carbonyl*-¹¹C]WAY-100635. *Psychoneuroendocrinology* 2014; **45**:1-10.
- *) Neudorfer C, Shanab K, Jurik A, Schreiber V, Neudorfer C, Vraka C, Schirmer E, Holzer W, Ecker G, Mitterhauser M, Wadsak W, Spreitzer H. Development of potential selective and reversible pyrazoline based MAO-B inhibitors as MAO-B PET tracer precursors and reference substances for the early detection of Alzheimer's disease. *Bioorganic & Medicinal Chemistry Letters* 2014; **24**: 4490-4495.
- *) Sesti A, Mayerhoefer M, Weber M, Anner W, Wadsak W, Dudczak R, Haug A, Karanikas G. Relevance of Calcitonin Cut-off in the Follow-Up of Medullary Thyroid Carcinoma for Conventional Imaging and 18-Fluorine-Fluorodihydroxyphenylalanine PET. *Anticancer Research* 2014; **34**:11.
- *) Kraus C, Baldinger P, Rami-Mark C, Gryglewski G, Kranz GS, Haeusler D, Hahn A, Wadsak W, Mitterhauser M, Rujescu D, Kasper S, Lanzenberger R. Exploration the impact of BDNF Val66Met genotype on serotonin transporter and serotonin-1A receptor binding. *PLoS one* 2014; **9**: e106810.
- *) Bauer M, Karch R, Zeitlinger M, Liu J, Koepp MJ, Asselin MC, Sisodiya SM, Hainfellner JA, Wadsak W, Mitterhauser M, Müller M, Pataraiia E, Langer O. In vivo P-glycoprotein function before and after epilepsy surgery. *Neurology* 2014; **83**:1326-1331.
- *) Vanicek T, Spies M, Rami-Mark C, Savli M, Höflich A, Kranz GS, Hahn A, Kutzelnigg A, Traub-Weidinger T, Mitterhauser M, Wadsak W, Hacker M, Volkow N, Kasper S, Lanzenberger R. The norepinephrine transporter in attention deficit and hyperactivity disorder investigated with (S,S)-[18F]FMeNER-D2. *JAMA Psychiatry* 2014;**71**:1340-9.
- *) Baldinger P, Höflich A, Mitterhauser M, Hahn A, Rami-Mark C, Spies M, Wadsak W, Hacker M, Lanzenberger R, Kasper S. Effects of Silexan on the serotonin-1A receptor and microstructure of the human brain: a randomized, placebo-controlled, double-blind, cross-over study with molecular and structural neuroimaging. *International Journal of Neuropsychopharmacology* 2014;**18**(4).
- *) Kranz G, Wadsak W, Kaufmann U, Savli M, Baldinger P, Gryglewski G, Haeusler D, Spies M, Mitterhauser M, Kasper S, Lanzenberger R. High-dose testosterone treatment increases serotonin transporter binding in transgender people. *Biological Psychiatry* 2015;**78**:525-33.

- *) Neudorfer C, Seddik A, Shanab K, Jurik A, Rami-Mark C, Holzer W, Ecker G, Mitterhauser M, Wadsak W, Spreitzer H. Synthesis and in silico evaluation of novel reference compounds for PET based investigations of the norepinephrine transporter. *Molecules* 2015;**20**:1712-1730.
- *) Haeusler D, Kuntner C, Nics L, Savli M, Zeilinger M, Wanek T, Karagiannis P, Lanzenberger RR, Langer O, Shanab K, Spreitzer H, Gerdenitsch W, Wadsak W, Hacker M, Mitterhauser M. [18F]FE@SUPPY: a suitable PET tracer for the adenosine A3 receptor? An in vivo study in rodents. *European Journal of Nuclear Medicine and Molecular Imaging* 2015;**42**:741-749.
- *) Baldinger P, Kraus C, Rami-Mark C, Gryglewski G, Kranz GS, Haeusler D, Hahn A, Spies M, Wadsak W, Mitterhauser M, Rujescu D, Kasper S, Lanzenberger R. Interaction between 5-HTTLPR and 5-HT1B genotype status enhances cerebral 5-HT1A receptor binding. *Neuroimage* 2015;**111**:505-512.
- *) Haeusler D, Grassinger L, Fuchshuber F, Hoerleinsberger WJ, Höftberger R, Leisser I, Girschele F, Shanab K, Spreitzer H, Gerdenitsch W, Hacker M, Wadsak W, Mitterhauser M. Hide and seek - a comparative autoradiographic in-vitro investigation of the adenosine A3 receptor. *European Journal of Nuclear Medicine and Molecular Imaging* 2015;**42**:928-939.
- *) Bauer M, Karch R, Zeitlinger M, Philippe C, Römermann K, Stanek J, Maier-Salamon A, Wadsak W, Jäger W, Hacker M, Müller M, Langer O. Approaching complete inhibition of P-glycoprotein at the human blood-brain barrier: an [¹¹C]verapamil PET study. *Journal of Cerebral Blood Flow and Metabolism* 2015;**35**:743-746.
- *) Neudorfer C, Shanab K, Holzer W, Rami-Mark C, Mitterhauser M, Wadsak W, Spreitzer H. 2-Fluoro-N-methyl-N-(((3S,4S)-4-[2-(trifluoromethyl)phenoxy]-3,4-dihydro-1H-isochromen-3-yl)methyl)ethanamine. *Molbank* 2015; M858; doi:10.3390/M858.
- *) Neudorfer C, Shanab K, Holzer W, Rami-Mark C, Mitterhauser M, Wadsak W, Spreitzer H. 2-Fluoro-N-methyl-N-(((3S,4S)-4-(2-methylphenoxy)-3,4-dihydro-1H-isochromen-3-yl)methyl)ethanamine. *Molbank* 2015; M862; doi:10.3390/M862.
- *) Neudorfer C, Eberherr N, Shanab K, Holzer W, Rami-Mark C, Mitterhauser M, Wadsak W, Spreitzer H. 1-(3-Amino-1-phenylpropyl)-3-(2-fluorophenyl)-1,3-dihydro-2H-benzimidazol-2-one. *Molbank* 2015; M867; doi:10.3390/M867.
- *) Leisser A, Pruscha K, Ubl P, Wadsak W, Mayerhöfer M, Mitterhauser M, Hacker M, Kramer G, Shariat S, Karanikas G, Hartenbach M, Haug A.R. Evaluation of fatty acid synthase in prostate cancer recurrence: SUV of [11C]acetate PET as a prognostic marker. *The Prostate* 2015;**75**:1760-7.
- *) Spick C, Polanec S, Mitterhauser M, Wadsak W, Anner P, Reiterits B, Haug AR, Hacker M, Beheshti M, Karanikas G. Detection of Bone Metastases Using 11C-Acetate PET in Patients with Prostate cancer with Biochemical Recurrence. *Anticancer Research* 2015;**35**:6787-91.
- *) Sigurdardottir HL, Kranz GS, Rami-Mark C, James GM, Vanicek T, Gryglewski G, Hienert M, Traub-Weidinger T, Mitterhauser M, Wadsak W, Hacker M, Rujescu D, Kasper S, Lanzenberger R. Effects of norepinephrine transporter gene variants on NET binding in ADHD and healthy controls investigated by PET. *Human Brain Mapping* 2016;**37**:884-95.

- *) Wenzel B, Mollitor J, Deuther-Conrad W, Dukic-Stefanovic S, Kranz M, Vranka C, Teodoro R, Günther R, Donat C, Ludwig FA, Fischer S, Smits R, Wadsak W, Mitterhauser M, Steinbach J, Hoepping A, Brust P. On the development of a novel non-peptidic 18F-labeled radiotracer for in vivo imaging of oxytocin receptors with positron emission tomography. *Journal of Medicinal Chemistry* 2016;**59**(5):1800-17.
- *) Philippe C, Haeusler D, Scherer T, Fuernsinn C, Zeilinger M, Wadsak W, Shanab K, Spreitzer H, Hacker M, Mitterhauser M. [18F]FE@SNAP – a specific PET-tracer for melanin-concentrating hormone receptor 1 imaging? *EJNMMI Research* 2016; **6**:31.
- *) Li X, Heber D, Rausch I, Beitzke D, Mayerhoefer ME, Rasul S, Kreissl M, Mitterhauser M, Wadsak W, Hartenbach M, Haug A, Zhang X, Loewe C, Beyer T, Hacker M. Quantitative assessment of atherosclerotic plaques on 18F-FDG PET/MRI: comparison with a PET/CT hybrid system. *European Journal of Nuclear Medicine and Molecular Imaging* 2016;**43**:1503-12.
- *) Bauer M, Römermann K, Karch R, Wulkersdorfer B, Stanek J, Philippe C, Maier-Salamon A, Haslacher H, Jungbauer C, Wadsak W, Jäger W, Löscher W, Hacker M, Zeitlinger M, Langer O. A pilot PET study to assess the functional interplay between P-glycoprotein and breast cancer resistance protein at the human blood-brain barrier. *Clinical Pharmacology & Therapeutics* 2016;**100**:131-41.
- *) Bauer M, Blaickner M, Philippe C, Wadsak W, Hacker M, Zeitlinger M, Langer O. Whole-body Distribution and Radiation Dosimetry of 11C-Elacridar and 11C-Tarividar in Humans. *Journal of Nuclear Medicine* 2016;**57**:1265-8.
- *) Leithner D, Baltzer PA, Magometschnigg HF, Wengert GJ, Karanikas G, Helbich TH, Weber M, Wadsak W, Pinker K. Quantitative Assessment of Breast Parenchymal Uptake in [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography: Correlation with Age, Background Parenchymal Enhancement, and Amount of Fibroglandular Tissue on Magnetic Resonance Imaging. *Journal of Nuclear Medicine* 2016;**57**:1518-1522.
- *) Pinker K, Andrzejewski P, Baltzer P, Polanec S, Sturdza A, Georg D, Helbich TH, Karanikas G, Grimm C, Polterauer S, Poetter R, Wadsak W, Mitterhauser M, Georg P. Multiparametric [18F]Fluorodeoxyglucose/[18F]Fluoromisonidazole Positron Emission Tomography/ Magnetic Resonance Imaging of Locally Advanced Cervical Cancer for the Non-invasive Detection of Tumor Heterogeneity: A Pilot Study. *PlosOne* 2016;**11**(5):e0155333.
- *) Vanicek T, Hahn A, Traub-Weidinger T, Hilger E, Spies M, Wadsak W, Lanzenberger R, Patarraia E, Asenbaum-Nan S. Differences in metabolic network connectivity in left- and right-sided mesial temporal lobe epilepsy using with [18F]FDG PET. *Scientific Reports* 2016;**6**:28513.
- *) Traub-Weidinger T, Weidinger P, Gröppel G, Karanikas G, Wadsak W, Kasprian G, Dorfer C, Dressler A, Muehlechner A, Hacker M, Czech T, Feucht M. Presurgical evaluation of pediatric epilepsy patients prior to hemispherotomy: the prognostic value of ¹⁸F-FDG PET. *J Neurosurg Pediatr.* 2016;**25**:683-688.
- *) Hahn A, Gryglewski G, Nics L, Hienert M, Rischka L, Vranka C, Sigurdardottir H, Vanicek T, James G, Seiger R, Wadsak W, Mitterhauser M, Hacker M, Kasper S, Lanzenberger R. Quantification of task-specific glucose metabolism with constant infusion of [18F]FDG. *Journal of Nuclear Medicine* 2016;**57**:1933-1940.

- *) Steiner E, Kazianka L, Breuer R, Hacker M, Wadsak W, Mitterhauser M, Stimpfl T, Reiter B, Karanikas G, Miholic J. ** -Postprandial pancreatic [11C]methionine uptake after pancreaticoduodenectomy mirrors basal beta cell function and insulin release. *European Journal of Nuclear Medicine and Molecular Imaging* 2017;**44**:509-516.
- *) Bauer M, Karch R, Tournier N, Cisternino S, Wadsak W, Hacker M, Marhofer P, Zeitlinger M, Langer O. Assessment of P-glycoprotein Transport Activity at the Human Blood-Retinal Barrier with (R)-11C-verapamil PET. *J Nucl Med.* 2017;**58**:678-681.
- *) Komorowski A, James GM, Philippe C, Gryglewski G, Bauer A, Hienert M, Spies M, Kautzky A, Vanicek T, Hahn A, Traub-Weidinger T, Winkler D, Wadsak W, Mitterhauser M, Hacker M, Kasper S, Lanzenberger R. Association of protein distribution and gene expression revealed by PET and post-mortem quantification in the serotonergic system of the human brain. *Cerebral Cortex* 2017;**27**:117-130.
- *) Vanicek T, Kutzelnigg A, Philippe C, Sigurdardottir HL, James GM, Hahn A, Kranz GS, Höflich A, Kautzky A, Traub-Weidinger T, Hacker M, Wadsak W, Mitterhauser M, Kasper S, Lanzenberger R. Altered interregional molecular associations of the serotonin transporter in attention deficit/hyperactivity disorder assessed with PET. *Human Brain Mapping* 2017;**38**:792-802.
- *) Gryglewski G, Rischka L, Philippe C, Hahn A, James GM, Klebermass E, Hienert M, Silberbauer L, Vanicek T, Kautzky A, Berroterán-Infante N, Nics L, Traub-Weidinger T, Mitterhauser M, Wadsak W, Hacker M, Kasper S, Lanzenberger R. Simple and rapid quantification of serotonin transporter binding using [11C]DASB bolus plus constant infusion. *Neuroimage* 2017; **149**:23–32.
- *) Vranka C, Nics L, Wagner KH, Hacker M, Wadsak W, Mitterhauser M. LogP, a yesterday's value? *Nucl Med Biol.* 2017;**50**:1-10.
- *) Zeilinger M, Pichler F, Nics L, Wadsak W, Spreitzer H, Hacker M, Mitterhauser M. New approaches for the reliable in-vitro assessment of binding affinity based on high-resolution real-time data acquisition of radioligand-receptor binding kinetics. *EJNMMI Research* 2017;**7**:22.
- *) James GM, Baldinger-Melich P, Philippe C, Kranz GS, Vanicek T, Hahn A, Gryglewski G, Hienert M, Spies M, Traub-Weidinger T, Mitterhauser M, Wadsak W, Hacker M, Kasper S, Lanzenberger R. Effects of selective serotonin reuptake inhibitors on interregional relation of serotonin transporter availability in major depression. *Frontiers in Human Neuroscience* 2017;**11**:48.
- *) Li S, Peck-Radosavljevic M, Ubl P, Wadsak W, Mitterhauser M, Rainer E, Pinter M, Wang H, Nanoff C, Kaczirek K, Haug A, Hacker M. The value of [11C]-acetate PET and [18F]-FDG PET in hepatocellular carcinoma before and after treatment with transarterial chemoembolization and bevacizumab. *European Journal of Nuclear Medicine and Molecular Imaging* 2017;**44**:1732-1741.
- *) Kautzky A, James GM, Philippe C, Baldinger-Melich P, Kraus C, Kranz GS, Vanicek T, Gryglewski G, Wadsak W, Mitterhauser W, Rujescu D, Kasper S, Lanzenberger R. The influence of the rs6295 gene polymorphism on serotonin-1A receptor distribution investigated with PET in patients with major depression applying machine learning. *Translational Psychiatry* 2017;**7**:e1150.

- *) Polanec SH, Andrzejewski P, Baltzer PAT, Helbich TH, Stiglbauer A, Georg D, Karanikas G, Susani M, Wadsak W, Margreiter M, Mitterhauser M, Brader P, Pinker K. Multiparametric [11C]Acetate positron emission tomography-magnetic resonance imaging in the assessment and staging of prostate cancer. *PLoS One* 2017;**12**(7):e0180790.
- *) Lassen ML, Muzik O, Beyer T, Hacker M, Ladefoged CN, Cal-Gonzalez J, Wadsak W, Rausch I, Langer O, Bauer M. Reproducibility of a quantitative brain PET protocol in PET-only and combined PET/MR imaging. *Frontiers in Neuroscience* 2017;**11**:396.
- *) Ahmadi Y, Kostenich G, Oron-Herman M, Wadsak W, Mitterhauser M, Orenstein A, Mirzaei S, Knoll P. In vivo magnetic resonance imaging of pancreatic tumors using iron oxide nanoworms targeted with PTR86 peptide. *Colloids and Surfaces B* 2017;**158**:423-430.
- *) Zeilinger M, Dumanic M, Pichler F, Budinsky L, Wadsak W, Pallitsch K, Spreitzer H, Lanzenberger R, Hacker M, Mitterhauser M, Philippe C. In vivo evaluation of radiotracers targeting the melaninconcentrating hormone receptor 1: [11C]SNAP-7941 and [18F]FE@SNAP reveal specific uptake in the ventricular system. *Scientific Reports* 2017; **14**;7:8054.
- *) Bauer M, Wulkersdorfer B, Karch R, Philippe C, Jäger W, Stanek J, Wadsak W, Hacker M, Zeitlinger M, Langer O. Effect of P-glycoprotein inhibition at the blood-brain barrier on brain distribution of (R)-[11C]verapamil in elderly versus young subjects. *British Journal of Clinical Pharmacology* 2017;**83**:1991-1999.
- *) Daniel M, Andrzejewski P, Sturdza A, Majercakova K, Baltzer P, Pinker K, Wadsak W, Mitterhauser M, Pötter R, Georg P, Helbich T, Georg D. Impact of hybrid PET/MR technology on multiparametric imaging and treatment response assessment of cervix cancer. *Radiother Oncol.* 2017;**125**:420-425.
- *) Fazekas J, Berroterán-Infante N, Rami-Mark C, Dumanic M, Matz M, Willmann M, Andreae F, Singer J, Wadsak W, Mitterhauser M, Jensen-Jarolim E. Development of a radiolabeled caninized anti-EGFR antibody for comparative oncology trials. *Oncotarget* 2017;**8**(47):83128-83141.
- *) Georg P, Andrzejewski P, Baltzer P, Daniel M, Wadsak W, Mitterhauser M, Sturdza A, Majercakova K, Karanikas G, Pötter R, Hacker M, Helbich T, Georg D, Pinker K. Changes in tumor biology during chemoradiation of cervix cancer assessed by multiparametric MRI and hypoxia PET. *Molecular Imaging and Biology* 2018;**20**(1):160-169.
- *) Nakuz TS, Berger E, El-Rabadi K, Wadsak W, Haug A, Hacker M, Karanikas G. Clinical Value of 18F-FDOPA PET/CT With Contrast Enhancement and Without Carbidopa Premedication in Patients with Insulinoma. *Anticancer Res.* 2018;**38**:353-358.
- *) Azizi A, Slavic I, Peyrl A, Rausch I, Theisen BE, Benkoe T, Aszmann O, Wadsak W, Weber M, Amann G, Kasprian G, Hojreh A, Hacker M, Staudenherz A, Traub-Weidinger T. Monitoring of Plexiform Neurofibroma in Children and Adolescents with Neurofibromatosis Type 1 by [18F]FDG-PET imaging. Is it of value in asymptomatic patients? *Pediatric Blood and Cancer* 2018;**65**(1).
- *) Grubmüller B, Baltzer P, D'Andrea D, Korn S, Haug AR, Hacker M, Grubmüller KH, Goldner GM, Wadsak W, Pfaff S, Babich J, Seitz C, Fajkovic H, Susani M, Mazal P, Kramer G, Shariat SF, Hartenbach M. 68Ga-PSMA 11

- ligand PET imaging in patients with biochemical recurrence after radical prostatectomy - diagnostic performance and impact on therapeutic decision-making. *Eur J Nucl Med Mol Imaging*. 2018;**45**:235-242.
- *) Li X, Heber D, Leike T, Beitzke D, Lu X, Zhang X, Wei Y, Mitterhauser M, Wadsak W, Kropf S, Wester HJ, Loewe C, Hacker M, Haug AR. [68Ga]Pentixafor-PET/MRI for the detection of Chemokine receptor 4 expression in atherosclerotic plaques. *Eur J Nucl Med Mol Imaging*. 2018;**45**:558-566.
 - *) Poetsch N, Woehrer A, Gesperger J, Furtner J, Haug AR, Wilhelm D, Widhalm G, Karanikas G, Weber M, Rausch I, Mitterhauser M, Wadsak W, Hacker M, Preusser M, Traub-Weidinger T. Visual and semiquantitative 11C-methionine PET: An independent prognostic factor for characterization of newly diagnosed and treatment naive gliomas. *Neuro Oncol*. 2018;**20**:411-419.
 - *) Bauer M, Matsuda A, Wulkersdorfer B, Philippe C, Traxl A, Özvegy-Laczka C, Stanek J, Nics L, Klebermass EM, Poschner S, Jaeger W, Patik I, Bakos E, Szakács G, Wadsak W, Hacker M, Zeitlinger M, Langer O. Influence of OATPs on hepatic disposition of erlotinib measured with positron emission tomography. *Clin Pharmacol Ther*. 2018;**104**:139-147.
 - *) Papp L, Poetsch N, Grahovac M, Schmidbauer V, Woehrer A, Preusser M, Mitterhauser M, Kiesel B, Wadsak W, Beyer T, Hacker M, Traub-Weidinger T. Glioma survival prediction with the combined analysis of in vivo 11C-MET-PET, ex vivo and patient features by supervised machine learning. *J Nucl Med*. 2018;**59**:892-899.
 - *) Hahn A, Gryglewski G, Nics L, Rischka L, Ganger S, Sigurdardottir H, Silberbauer L, Vanicek T, Kautzky A, Wadsak W, Mitterhauser M, Hartenbach M, Hacker M, Kasper S, Lanzenberger R. Task-relevant brain networks identified with simultaneous PET/MR imaging of metabolism and connectivity. *Brain Structure and Function* 2018;**223**:1369-1378.
 - *) Kranz GS, Hahn A, Kraus C, Spies M, Pichler V, Jungwirth J, Mitterhauser M, Wadsak W, Windischberger C, Kasper S, Lanzenberger R. Probing the association between serotonin-1A autoreceptor binding and amygdala reactivity in healthy volunteers. *NeuroImage* 2018;**171**:1-5.
 - *) Anner P, Mayerhöfer M, Wadsak W, Dudczak R, Haug A, Hacker M, Karanikas G. [¹⁸F]FDG-PET/CT and MRI for initial pelvic lymph node staging in patients with cervical carcinoma - potential usefulness of [¹⁸F]FDG-PET/MRI. *Oncol Lett*. 2018;**15**:3951-3956.
 - *) Vranka C, Mijailovic S, Fröhlich V, Zeilinger M, Klebermass EM, Wadsak W, Wagner KH, Hacker M, Mitterhauser M. Expanding LogP: Present possibilities. *Nucl Med Biol* 2018;**58**:20-32.
 - *) Vranka C, Dumanic M, Racz T, Pichler F, Balber T, Philippe C, Klebermass EM, Wagner KH, Hacker M, Wadsak W, Mitterhauser M. A new Method Measuring the Interaction of Radiotracers with the human P-glycoprotein (P-gp) Transporter. *Nucl Med Biol*. 2018;**60**:29-36.
 - *) Balber T, Singer J, Berroterán-Infante N, Dumanic M, Fetty L, Fazekas-Singer J, Vranka C, Nics L, Bergmann M, Pallitsch K, Spreitzer H, Wadsak W, Hacker M, Jensen-Jarolim E, Viernstein H, Mitterhauser M. Preclinical in vitro and in vivo evaluation of [¹⁸F]FE@SUPPY for cancer PET-imaging: Limitations of a xenograft model for colorectal cancer. *Contrast Media & Molecular Imaging* 2018:1269830.

- *) Nejabat M, Leisser A, Karanikas G, Wadsak W, Mitterhauser M, Mayerhöfer M, Kienbacher C, Trauner M, Hacker M, Haug AR. [11C]acetate PET as a tool for diagnosis of liver steatosis. *Abdominal Radiology* (NY). 2018;**43**:2963-2969.
- *) Gryglewski G, Seiger R, James GM, Godbersen GM, Komorowski A, Michenthaler P, Hahn A, Wadsak W, Mitterhauser M, Kasper S, Lanzenberger R. Spatial analysis and prediction of the human whole-brain transcriptome. *Neuroimage* 2018;**176**:259-267.
- *) Mayerhoefer ME, Jaeger U, Staber P, Raderer M, Wadsak W, Pfaff S, Kornauth C, Senn D, Weber M, Wester HJ, Skrabs C, Haug A. [68Ga]Ga-Pentixafor PET/MRI for CXCR4 Imaging of Chronic Lymphocytic Leukemia: Preliminary Results. *Invest Radiol*. 2018;**53**:403-408.
- *) Rischka L, Gryglewski G, Pfaff S, Vanicek T, Hienert M, Klöbl M, Hartenbach M, Haug A, Wadsak W, Mitterhauser M, Hacker M, Kasper S, Lanzenberger R, Hahn A. Reduced task durations in functional PET imaging with [18F]FDG approaching that of functional MRI. *NeuroImage* 2018;**181**:323-330.
- *) Philippe C, Zeilinger M, Dumanic M, Pichler F, Fetty L, Vranka C, Balber T, Wadsak W, Pallitsch K, Spreitzer H, Lanzenberger R, Hacker M, Mitterhauser M. SNAPshots of the MCHR1: A comparison between the PET-tracers [18F]FE@SNAP and [11C]SNAP-7941. *Molecular Imaging and Biology* 2018; Jun 13. doi: 10.1007/s11307-018-1212-0. **[Epub ahead of print]**
- *) Grubmüller B, Baltzer P, Hartenbach S, D'Andrea D, Helbich TH, Haug AR, Goldner GM, Wadsak W, Pfaff S, Mitterhauser M, Balber T, Berroteran-Infante N, Grahovac M, Babich J, Seitz C, Kramer G, Susani M, Mazal P, Kenner L, Shariat SF, Hacker M, Hartenbach M. PSMA ligand PET/MRI for primary prostate cancer: Staging performance and clinical impact. *Clinical Cancer Research* 2018;**24**:6300-6307.
- *) Grubmüller B, Senn D, Kramer G, Baltzer P, D'Andrea D, Grubmüller KH, Mitterhauser M, Eidherr H, Haug AR, Wadsak W, Pfaff S, Shariat SF, Hacker M, Hartenbach M. Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer. *Eur J Nucl Med Mol Imaging*. 2018 Dec 19. doi: 10.1007/s00259-018-4236-4. **[Epub ahead of print]**
- *) James GM, Gryglewski G, Vanicek T, Berroterán-Infante N, Philippe C, Kautzky A, Nics L, Vranka C, Godbersen GM, Unterholzner J, Sigurdardottir HL, Spies M, Seiger R, Kranz GS, Hahn A, Mitterhauser M, Wadsak W, Bauer A, Hacker M, Kasper S, Lanzenberger R. Parcellation of the Human Cerebral Cortex Based on Molecular Targets in the Serotonin System Quantified by Positron Emission Tomography In vivo. *Cereb Cortex*. 2019;**29**:372-382.
- *) Spies M, James GM, Vranka C, Philippe C, Hienert M, Gryglewski G, Komorowski A, Kautzky A, Silberbauer L, Pichler V, Kranz GS, Nics L, Balber T, Baldinger-Melich P, Vanicek T, Spurny B, Winkler-Pjrek E, Wadsak W, Mitterhauser M, Hacker M, Kasper S, Lanzenberger R, Winkler D. Brain monoamine oxidase A in seasonal affective disorder and treatment with bright light therapy. *Transl Psychiatry*. 2018;**8**:198.
- *) Bauer M, Karch R, Wulkersdorfer B, Philippe C, Nics L, Klebermass EM, Weber M, Poschner S, Haslacher H, Jaeger W, Tournier N, Wadsak W, Hacker M, Zeitlinger M, Langer OA. Proof-of-Concept Study to Inhibit ABCG2- and ABCB1-Mediated Efflux Transport at the Human Blood-Brain Barrier. *J Nucl Med*. 2018 Sep 20. pii: jnumed.118.216432. doi: 10.2967/jnumed.118.216432. **[Epub ahead of print]**

- *) Bauer M, Traxl A, Matsuda A, Karch R, Philippe C, Nics L, Klebermass EM, Wulkersdorfer B, Weber M, Poschner S, Tournier N, Jäger W, Wadsak W, Hacker M, Wanek T, Zeitlinger M, Langer O. Effect of Rifampicin on the Distribution of [11C]Erlotinib to the Liver, a Translational PET Study in Humans and in Mice. *Mol Pharm.* 2018;**15**:4589-4598.
- *) Rischka L, Gryglewski G, Pfaff S, Vanicek T, Hienert M, Klöbl M, Hartenbach M, Haug A, Wadsak W, Mitterhauser M, Hacker M, Kasper S, Lanzenberger R, Hahn A. Reduced task durations in functional PET imaging with [18F]FDG approaching that of functional MRI. *Neuroimage.* 2018;**181**:323-330.
- *) Berroterán-Infante N, Tadić M, Hacker M, Wadsak W, Mitterhauser M. Binding Affinity of Some Endogenous and Synthetic TSPO Ligands Regarding the rs6971 Polymorphism. *Int J Mol Sci.* 2019;**20**(3).
- *) Kautzky A, James GM, Philippe C, Baldinger-Melich P, Kraus C, Kranz GS, Vanicek T, Gryglewski G, Hartmann AM, Hahn A, Wadsak W, Mitterhauser M, Rujescu D, Kasper S, Lanzenberger R. Epistasis of HTR1A and BDNF risk genes alters cortical 5-HT1A receptor binding: PET results link genotype to molecular phenotype in depression. *Translational Psychiatry* 2019;**9**:5.
- *) Andrzejewski P, Wengert G, Helbich TH, Magometschnigg H, Georg D, Hacker M, Baltzer P, Clauser P, Kapetas P, Georg P, Wadsak W, Pinker K. Multiparametric [18F]FDG/[18F]FMISO PET-MRI at 3T for Insights Into Breast Cancer Heterogeneity and Correlation with Patient Outcomes: First Clinical Experience. *Contrast Media and Molecular Imaging* 2019:1307247. eCollection 2019.
- *) Baldinger-Melich P, Gryglewski G, Philippe C, James G, Vranka C, Silberbauer L, Balber T, Vanicek T, Pichler V, Unterholzner J, Kranz G, Hahn A, Winkler D, Mitterhauser M, Wadsak W, Hacker M, Kasper S, Frey R, Lanzenberger R. The effect of electroconvulsive therapy on cerebral monoamine oxidase A expression in treatment-resistant depression investigated using positron emission tomography. *Brain Stimulation* 2019; Jan 2. pii: S1935-861X(18)31395-0. doi: 10.1016/j.brs.2018.12.976. **[Epub ahead of print]**
- *) Magometschnigg H, Pinker K, Helbich T, Brandstetter A, Rudas M, Nakuz T, Baltzer P, Wadsak W, Hacker M, Weber M, Dubsky P, Filipits M. PIK3CA Mutational Status Is Associated with High Glycolytic Activity in ER+/HER2- Early Invasive Breast Cancer: a Molecular Imaging Study Using [18F]FDG PET/CT. *Molecular Imaging and Biology* 2019; Jan 16. doi: 10.1007/s11307-018-01308-z. **[Epub ahead of print]**
- *) Tournier N, Bauer M, Pichler V, Nics L, Klebermass EM, Bamminger K, Poschner S, Matzneller P, Weber M, Karch W, Caillé F, Auvity S, Marie S, Jäger W, Wadsak W, Hacker M, Zeitlinger M, Langer. Impact of P-glycoprotein function on the brain kinetics of CNS-active weak P-glycoprotein substrates assessed using [11C]metoclopramide PET imaging in humans. *J Nucl Med.* 2019; Jan 10. pii: jnumed.118.219972. doi: 10.2967/jnumed.118.219972. **[Epub ahead of print]**
- *) Lötsch F, Waneck F, Groger M, Auer H, Kaczirek K, Rausch I, Wadsak W, Hacker M, Ramharter M, Karanikas G. FDG-PET/MRI Imaging for the Management of Alveolar Echinococcosis: Clinical Experience at a Reference Centre in Austria. *Tropical Medicine & International Health* 2019; Mar 9. doi: 10.1111/tmi.13228. **[Epub ahead of print]**
- *) Beer LB, Hochmair M, Schwabel B, Kifjak D, Haug AR, Wadsak W, Fuereder T, Fabikan H, Fazekas A, Schwab S, Mayerhoefer ME, Herold C, Prosch H. Comparison of RECIST, iRECIST, and PERCIST for the evaluation of

response to PD1-blockage therapy in patients with non-small cell lung cancer. *Clinical Nuclear Medicine*. 2019; **in press**.

- *) Vranka C, Pichler V, Pfaff S, Balber T, Hacker M, Mitterhauser M, Wadsak W, Philippe C. Optimized automated synthesis and real-time kinetic evaluation of [¹¹C]SNAP-7941. *Journal of Visualized Experiments*. 2019; **in press**.

Buch-Kapitel

- *) Philippe C, Mitterhauser M, Wadsak W. Synthesis of 2-(4-N-[¹¹C]methylaminophenyl)-6-hydroxybenzothiazole ([¹¹C]6-OH-BTA-1; [¹¹C]PIB). Chapter 18. In: *Radiochemical Syntheses, Volume 1, Radiopharmaceuticals for Positron Emission Tomography* Scott PJH, Hockley BG (eds.); 1st edition, John Wiley & Sons; 2012.
- *) Haeusler D, Mitterhauser M, Wadsak W. Synthesis of 3-amino-4-[2-(N-methyl-N-[¹¹C]methyl-amino-methyl)phenylsulfanyl]-benzotrile ([¹¹C]DASB). Chapter 28. In: *Radiochemical Syntheses, Volume 1, Radiopharmaceuticals for Positron Emission Tomography*; Scott PJH, Hockley BG (eds.); 1st edition, John Wiley & Sons; 2012.
- *) Eidherr H, Girschele F, Mitterhauser M, Wadsak W. Synthesis of [⁶⁸Ga]gallium DOTA-(Tyr3)-octreotide acetata (⁶⁸Ga-DOTATOC). Chapter 32. In: *Radiochemical Syntheses, Volume 1, Radiopharmaceuticals for Positron Emission Tomography*; Scott PJH, Hockley BG (eds.); 1st edition, John Wiley & Sons; 2012.
- *) Pichler V, Berroterán-Infante N, Ozenil M, Pfaff S, Philippe C, Wadsak W. Carbon-11 Tracers And Applications. Chapter 12. In: *Radiopharmaceutical Chemistry*; Lewis J, Zeglis B, Windhorst B (eds); 1st edition, Springer; 2019. **[in press]**